Table 5 Tolerability of NVP-based HAART among the three groups.
Tolerability outcomes | Not receiving fluconazole | Receiving fluconazole | Pvalue | |
|---|---|---|---|---|
(n = 225) | 400 mg/week (n = 392) | 200 mg/day (n = 69) | ||
On NVP-based HAART at six months | 174 (77.3%) | 309 (78.8%) | 58 (84.1%) | 0.532 |
Reasons of discontinuation | 0.448 | |||
Adverse events | 26 (11.5%) | 29 (7.4%) | 3 (4.3%) | |
Skin rashes | 25/26 (96.2%) | 26/29 (89.7%) | 3 of 3 (100.0%) | |
Hepatotoxicity | 1/26 (2.8%) | 3/29 (10.3%) | - | |
Death | 1 (0.4%) | 8 (2.0%) | - | |
Loss to follow-up | 20 (8.9%) | 39 (9.9%) | 7 (10.1%) | |
Refer | 4 (1.8%) | 7 (1.8%) | 1 (1.4%) | |